Morepen Labs Q1 FY27 Results: Profit Soars, Dividend Declared, CMD Reappointed
Morepen Laboratories reported its Q1 FY27 results, with a significant increase in profit. The board approved a dividend, setting the record date for September 19, 2026. Mr. Sushil Suri was reappointed as Chairman & Managing Director for three years, effective October 20, 2026. The 41st AGM is scheduled for September 26, 2026.
The approval of financial results, dividend declaration, and reappointment of the CMD are material events that can significantly impact investor sentiment and the company's strategic direction.
The company reported strong financial results, declared a dividend, and reappointed its key leadership, indicating positive operational and strategic stability.
Morepen Laboratories Limited announced the outcome of its Board of Directors meeting held on Tuesday, August 4, 2026. The board approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
The company declared a record date of Saturday, September 19, 2026, for determining eligible members to receive a final dividend for the financial year ended March 31, 2026, subject to member approval at the upcoming 41st Annual General Meeting (AGM).
Furthermore, the board approved the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, effective from October 20, 2026, to October 19, 2029, pending member approval at the 41st AGM. Mr. Suri, a qualified Chartered Accountant with over 30 years of experience in the pharmaceutical industry, is the brother of Mr. Sanjay Suri, the company's Managing Director.
The board also approved, subject to member approval at the 41st AGM, an extension of the timeline for hiving off the Medical Devices Business into its subsidiary, Morepen Medipath Limited.
The notice for the 41st AGM has been scheduled for Saturday, September 26, 2026, to be held through video conferencing.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.